DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Keryx Biopharmaceuticals (NASDAQ: KERX)

10.33 -0.33 (-3.10%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

KERX $10.33 -3.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.69
Previous Close $10.66
Daily Range $10.22 - $10.75
52-Week Range $8.84 - $18.48
Market Cap $1.1B
P/E Ratio -7.84
Dividend (Yield) $0.00 (0.0%)
Volume 1,054,282
Average Daily Volume 2,008,994
Current FY EPS -$0.94




Drug Makers

Keryx Biopharmaceuticals (KERX) Description

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Website:

News & Commentary

Why Keryx Biopharmaceuticals Shares Plummeted 14% in January

Keryx Biopharmaceuticals' shareholders have had a rough start this year. Find out why Keryx shares have swooned and whether or not this dip represents a genuine buying opportunity.

Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics ...

Keryx Biopharmaceuticals (KERX) Jumps: Stock Up 14.8% - Tale of the Tape

Keryx Biopharmaceuticals (KERX) Jumps: Stock Up 14.8% - Tale of the Tape

Keryx Biopharmaceuticals (KERX) Highlighted As Today's Perilous Reversal Stock

Monday's ETF Movers: XBI, IEO

Barbarian At The Gate: Keryx Biopharmaceuticals (KERX)

Keryx Biopharmaceuticals: Watch For An FDA Warning Letter

Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data

Keryx Biopharmaceuticals Posts In-line Loss, Revenue Beat - Analyst Blog

The 52-Week Low Club for Monday

Keryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q1 2015 Results - Earnings Call Transcript

See More KERX News...

KERX's Top Competitors

KERX $10.33 (-3.10%)
Current stock: KERX
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
BIIB $398.68 (-0.62%)
Current stock: BIIB